Nabriva Therapeutics (NBRV) Short Interest Ratio & Short Volume → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free NBRV Stock Alerts Add Compare Share Share Short InterestStock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsSocial Media Nabriva Therapeutics Short Interest DataCurrent Short Volume44,600 sharesPrevious Short Volume52,200 sharesChange Vs. Previous Month-14.56%Dollar Volume Sold Short$70,637.48Short Interest Ratio / Days to Cover3.7Last Record DateJuly 15, 2023Outstanding Shares32,015,000 sharesFloat Size2,970,000 sharesShort Percent of Float1.50%Today's Trading Volume0 sharesAverage Trading Volume29,344 sharesToday's Volume Vs. Average0% Short Selling Nabriva Therapeutics ? Sign up to receive the latest short interest report for Nabriva Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatNBRV Short Interest Over TimeNBRV Days to Cover Over TimeNBRV Percentage of Float Shorted Over Time Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. Nabriva Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/202344,600 shares $70,637.48 -14.6%1.5%3.7 $1.58 6/30/202352,200 shares $78,822.00 +47.9%1.8%4.3 $1.51 6/15/202335,300 shares $52,950.00 +27.4%1.2%2.6 $1.50 5/31/202327,700 shares $42,935.00 +12.2%0.9%1.9 $1.55 5/15/202324,700 shares $41,249.00 +2.9%0.8%1.6 $1.67 4/30/202324,000 shares $38,402.40 +3.9%0.8%1.9 $1.60 Get the Latest News and Ratings for NBRV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 4/15/202323,100 shares $34,650.00 -31.9%0.8%1.4 $1.50 3/31/202333,900 shares $59,219.91 +29.9%1.2%1.2 $1.75 3/15/202326,100 shares $41,238.00 -10.9%0.9%0.6 $1.58 2/28/202329,300 shares $52,447.00 -8.4%1.0%0.6 $1.79 2/15/202332,000 shares $58,240.00 -19.0%1.1%0.4 $1.82 1/31/202339,500 shares $62,805.00 -33.2%1.4%0.4 $1.59 1/15/202359,100 shares $88,059.00 +16.6%2.1%0.7 $1.49 12/30/202250,700 shares $95,823.00 +6.5%1.8%0.6 $1.89 12/15/202247,600 shares $91,868.00 -82.0%1.7%0.6 $1.93 11/30/2022264,900 shares $596,025.00 +376.4%9.5%1.3 $2.25 11/15/202255,600 shares $125,667.12 -16.6%2.0%0.4 $2.26 10/31/202266,700 shares $169,418.00 -38.6%2.7%0.4 $2.54 10/15/2022108,600 shares $259,554.00 -10.5%4.5%0.7 $2.39 9/30/2022121,300 shares $252,304.00 +395.1%6.1%0.8 $2.08 9/15/202224,500 shares $163,598.75 -95.4%1.0%0.2 $6.68 8/31/2022532,200 shares $87,615.55 -13.0%N/A0.7 $0.16 8/15/2022611,800 shares $124,195.40 -13.7%N/A0.7 $0.20 7/31/2022709,000 shares $127,194.60 +24.2%N/A0.9 $0.18 7/15/2022571,100 shares $108,109.23 +6.9%N/A0.7 $0.19 6/30/2022534,100 shares $97,206.20 +0.8%N/A0.8 $0.18 6/15/2022529,700 shares $100,643.00 +3.9%N/A1 $0.19 5/31/2022509,600 shares $105,487.20 -4.8%N/A1 $0.21 5/15/2022535,500 shares $120,326.85 -21.0%N/A1.1 $0.22 4/30/2022677,700 shares $212,120.10 +12.6%N/A1.6 $0.31 4/15/2022602,100 shares $222,777.00 -25.9%N/A1.5 $0.37 3/31/2022812,800 shares $341,376.00 +29.0%N/A1.9 $0.42 3/15/2022629,900 shares $256,369.30 -16.2%N/A1.2 $0.41 2/28/2022751,300 shares $341,090.20 -15.1%N/A1.3 $0.45 2/15/2022885,200 shares $453,842.04 +30.8%N/A1.3 $0.51 1/31/2022676,800 shares $326,894.40 -6.1%N/A0.8 $0.48 1/15/2022720,400 shares $385,414.00 -18.7%N/A0.8 $0.54 12/31/2021885,800 shares $530,594.20 -20.2%N/A1.1 $0.60 12/15/20211,110,000 shares $688,311.00 No ChangeN/A1.5 $0.62 11/30/20211,110,000 shares $864,690.00 -5.1%N/A1.5 $0.78Mysterious Gold Leverage Just Announced (Ad)World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. NBRV Short Interest - Frequently Asked Questions What is Nabriva Therapeutics' current short interest? Short interest is the volume of Nabriva Therapeutics shares that have been sold short but have not yet been closed out or covered. As of July 15th, traders have sold 44,600 shares of NBRV short. 1.50% of Nabriva Therapeutics' shares are currently sold short. Learn More on Nabriva Therapeutics' current short interest. What is a good short interest ratio for Nabriva Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NBRV shares currently have a short interest ratio of 4.0. Learn More on Nabriva Therapeutics's short interest ratio. What is a good short interest percentage for Nabriva Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.50% of Nabriva Therapeutics' floating shares are currently sold short. Is Nabriva Therapeutics' short interest increasing or decreasing? Nabriva Therapeutics saw a decline in short interest in the month of July. As of July 15th, there was short interest totaling 44,600 shares, a decline of 14.6% from the previous total of 52,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Nabriva Therapeutics' float size? Nabriva Therapeutics currently has issued a total of 32,015,000 shares. Some of Nabriva Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Nabriva Therapeutics currently has a public float of 2,970,000 shares. How does Nabriva Therapeutics' short interest compare to its competitors? 1.50% of Nabriva Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Nabriva Therapeutics: Aadi Bioscience, Inc. (6.31%), Rockwell Medical, Inc. (2.40%), Jaguar Health, Inc. (5.20%), Immuneering Co. (13.23%), Clene Inc. (0.12%), Apollomics, Inc. (0.32%), NextCure, Inc. (0.54%), Bolt Biotherapeutics, Inc. (8.63%), CalciMedica, Inc. (0.71%), BioLineRx Ltd. (0.98%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($3.75 billion), Charter Communications, Inc. ($3.17 billion), Occidental Petroleum Co. ($2.86 billion), Rivian Automotive, Inc. ($2.29 billion), T. Rowe Price Group, Inc. ($2.13 billion), Royal Caribbean Cruises Ltd. ($2.05 billion), Palantir Technologies Inc. ($2.04 billion), Extra Space Storage Inc. ($1.98 billion), Enphase Energy, Inc. ($1.66 billion), and Tractor Supply ($1.61 billion). View all of the most shorted stocks. What does it mean to sell short Nabriva Therapeutics stock? Short selling NBRV is an investing strategy that aims to generate trading profit from Nabriva Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Nabriva Therapeutics? A short squeeze for Nabriva Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of NBRV, which in turn drives the price of the stock up even further. How often is Nabriva Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NBRV, twice per month. The most recent reporting period available is July, 15 2023. More Short Interest Resources from MarketBeat Related Companies: AADI Short Interest Data RMTI Short Interest Data JAGX Short Interest Data IMRX Short Interest Data CLNN Short Interest Data APLM Short Interest Data NXTC Short Interest Data BOLT Short Interest Data CALC Short Interest Data BLRX Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NBRV) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press